| 产品详情 |
| Edit |   |
|---|
| Product Name | CCG-203971 |
|---|
| Description | Purity >90%. Signaling through small G proteins of the RhoA subfamily, including RhoC, induces actin-regulated cytosolic-to-nuclear translocation of the oncogene product megakaryoblastic leukemia 1 (MKL1), which binds to serum response factor (SRF). The MKL1/SRF complex, in turn, activates the transcription of serum response element (SRE) regulated genes, stimulating cell migration, a process that is central to metastasis. CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 µM), with 87% inhibition of SRE activation achieved at 100 µM. This compound also inhibits PC-3 cell migration (IC50 = 4.2 µM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-(4-chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide |
|---|
| Gene, Accession, CAS # | CAS: 1443437-74-8 |
|---|
| Catalog # | LS-H7025 |
|---|
| Price | |
|---|
| Order / More Info | CCG-203971 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|